Schonfeld Strategic Advisors’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Schonfeld Strategic Advisors’s Portfolio TCRR Stock Details TCRR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-26,600	Closed	-$26.6K	–	2887
2022 Q4	$26.6K	Sell	26,600 -8,800	-25%	-$11.9K	﹤0.01%	2305
2022 Q3	$64K	Sell	35,400 -29,000	-45%	-$84.1K	﹤0.01%	2610
2022 Q2	$187K	Sell	64,400 -10,000	-13%	-$24.7K	﹤0.01%	1930
2022 Q1	$205K	Buy	74,400 +43,200	+138%	+$136K	﹤0.01%	1944
2021 Q4	$145K	Sell	31,200 -210,561	-87%	-$1.32M	﹤0.01%	1821
2021 Q3	$2.06M	Buy	+241,761	New	+$3.42M	0.02%	702

Other funds holding TCRR

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Schonfeld Strategic Advisors's TCRR Position: Q1 2023 in Review

Schonfeld Strategic Advisors sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q1 2023, closing a stake of 26,600 shares — an estimated $26.6K sold.

Schonfeld Strategic Advisors first reported a position in TCRR in Q3 2021 and held it in 6 quarters. The position peaked at $2.06M in Q3 2021. 59 funds tracked by Wall St. Rank hold TCRR as of Q1 2023.

Schonfeld Strategic Advisors reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Schonfeld Strategic Advisors sold 26,600 TCR2 Therapeutics Inc. Common Stock shares in Q1 2023, an estimated $26.6K.
Schonfeld Strategic Advisors first reported a position in TCR2 Therapeutics Inc. Common Stock in Q3 2021 and held it in 6 quarters.
Schonfeld Strategic Advisors's TCR2 Therapeutics Inc. Common Stock position peaked at $2.06M in Q3 2021.
59 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q1 2023.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2023, filed 15 May 2023.